SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT

The present disclosure relates to the pharmaceutical field. More specifically, it relates to methods for treating a tumor in a human subject in need thereof, said method comprising administering a therapeutically efficient amount of an anti-BTN3A antibody which induces the activation of Vγ9Vδ2 T cel...

Full description

Saved in:
Bibliographic Details
Main Authors VALENTIN, Emmanuel, DE GASSART, Aude, FROHNA, Paul
Format Patent
LanguageEnglish
French
German
Published 24.07.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to the pharmaceutical field. More specifically, it relates to methods for treating a tumor in a human subject in need thereof, said method comprising administering a therapeutically efficient amount of an anti-BTN3A antibody which induces the activation of Vγ9Vδ2 T cells, in combination with a therapeutically efficient amount of an anti-PD1/PDL1 treatment, wherein said subject is having relapsed or refractory tumors to anti-PD1/PDL1 treatment.
Bibliography:Application Number: EP20220801343